![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
TP Kenakin and D Beek
Both prenalterol and pirbuterol are partial agonists (when compared to isoproterenol) in rat left atria. Schild analysis with the beta-1 adrenoceptor selective antagonist atenolol indicated that all three agonists stimulate beta-1 adrenoceptors in this preparation. Atria from rats implanted with mini-osmotic pumps which delivered isoproterenol (400 micrograms kg-1 hr-1) s.c. for 4 days were 9 times less sensitive than control, to isoproterenol, and produced no responses to either prenalterol or pirbuterol. Schild analysis with atenolol on these desensitized atria indicated a homogeneous population of beta-1 adrenoceptors. In the desensitized atria, both prenalterol and pirbuterol functioned as competitive antagonists of responses to isoproterenol and Schild analysis yielded estimates of the equilibrium dissociation constants (Kp) of prenalterol (0.09 micron) and pirbuterol (2 micron) in these tissues. The estimates of Kp were utilized to calculate the relative efficacy of pirbuterol and prenalterol; pirbuterol was shown to have 2.3 times the efficacy of prenalterol on beta-1 adrenoceptors. The implications of this method as a means of calculating the Kp for partial agonists are discussed. These data also serve as a caveat to the use of pirbuterol in the determination of functional cardiac beta adrenoceptor subtypes in experimental animals and in man.
This article has been cited by other articles:
|
|
 |
|
  T. Hirose, Y. Uwahodo, S. Yamada, T. Miwa, T. Kikuchi, H. Kitagawa, K. D. Burris, C. A. Altar, and T. Nabeshima Mechanism of Action of Aripiprazole Predicts Clinical Efficacy and a Favourable Side-Effect Profile J Psychopharmacol, September 1, 2004; 18(3): 375 - 383. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Brkovic, A. Hattenberger, E. Kostenis, T. Klabunde, S. Flohr, M. Kurz, S. Bourgault, and A. Fournier Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1200 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D. Burris, T. F. Molski, C. Xu, E. Ryan, K. Tottori, T. Kikuchi, F. D. Yocca, and P. B. Molinoff Aripiprazole, a Novel Antipsychotic, Is a High-Affinity Partial Agonist at Human Dopamine D2 Receptors J. Pharmacol. Exp. Ther., July 1, 2002; 302(1): 381 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. R. Kapusta, J.-K. Chang, and V. A. Kenigs Central Administration of [Phe1Psi (CH2-NH)Gly2]Nociceptin(1-13)-NH2 and Orphanin FQ/Nociceptin (OFQ/N) Produce Similar Cardiovascular and Renal Responses in Conscious Rats J. Pharmacol. Exp. Ther., April 1, 1999; 289(1): 173 - 180. [Abstract] [Full Text]
|
|
|
|
|
|
A. Zanesco, R. C. Spadari-Bratfisch, and L. A. Barker Sino-Aortic Denervation Causes Right Atrial Beta Adrenoceptor Down-Regulation J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 677 - 685. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
